Le dernier exercice comptable publié pour cette entreprise remonte à 2023. Les données ci-dessous peuvent ne plus refléter sa situation actuelle.

ATLANCHIM PHARMA : revenue, balance sheet and financial ratios

ATLANCHIM PHARMA is a French company founded 18 years ago, specialized in the sector Recherche-développement en autres sciences physiques et naturelles. Based in SAINT-HERBLAIN (44800), this company of category PME shows in 2023 a revenue of 881 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-08-08

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Synthèse

Santé financière : Fragile

Signal structurel : exploitation déficitaire (EBE négatif).

In summary, ATLANCHIM PHARMA is currently loss-making, which weighs on its accounts. Its financial structure is solid, with debt well contained relative to its sector.

Financial history - ATLANCHIM PHARMA (SIREN 504005612)
Indicator 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 881 264 € 799 699 € 1 118 638 € 768 051 € 837 542 € 982 039 € 851 641 € 725 444 €
Net income -36 409 € -83 331 € 42 227 € 55 722 € 40 100 € 207 723 € 124 043 € -185 753 €
EBITDA -148 753 € -277 741 € -26 577 € -81 008 € -121 663 € 72 093 € 20 797 € -209 039 €
Net margin -4.1% -10.4% 3.8% 7.3% 4.8% 21.2% 14.6% -25.6%

Revenue and income statement

In 2023, ATLANCHIM PHARMA achieves revenue of 881 k€. Revenue is growing positively over 8 years (CAGR: +1.3%). Vs 2022, growth of +10% (800 k€ -> 881 k€). After deducting consumption (52 k€), gross margin stands at 829 k€, i.e. a rate of 94%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -149 k€, representing -16.9% of revenue. Positive scissor effect: EBITDA margin improves by +17.9 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -36 k€ (-4.1% of revenue), which will impact equity.

Revenue (2023) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

881 264 €

Gross margin (2023) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

829 044 €

EBITDA (2023) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-148 753 €

EBIT (2023) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-168 007 €

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-36 409 €

EBITDA margin (2023) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-16.7%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 2%. This ratio is more favorable than the sector median (3.7%). Financial autonomy (= Equity / Total assets x 100) reaches 10%. This ratio is less favorable than the sector median (51.2%) and warrants attention.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

2.02%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

10.05%

Cash flow / Revenue (2023) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-1.99%

Repayment capacity (2023) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-0.09

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

24.9%

Solvency indicators evolution
ATLANCHIM PHARMA

Sector positioning

Debt ratio
2.02% 2023
Q1: 0.0%
Med: 3.68%
Q3: 43.53%
Good -32 pts over 2 years

In 2023, the debt ratio of ATLANCHIM PHARMA (2.0%) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
10.05% 2023
Q1: 25.66%
Med: 51.2%
Q3: 73.99%
Watch

In 2023, the financial autonomy of ATLANCHIM PHARMA (10.1%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 1.04. This ratio is less favorable than the sector median (2.8) and warrants attention.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

1.04

Interest coverage (2023) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-1.58

Liquidity indicators evolution
ATLANCHIM PHARMA

Sector positioning

Liquidity ratio
1.04 2023
Q1: 1.48
Med: 2.76
Q3: 5.19
Watch

In 2023, the liquidity ratio of ATLANCHIM PHARMA (1.04) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 131 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 441 days. Excellent situation: suppliers finance 310 days of the operating cycle (retail model). Inventory turnover is 147 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 300 days of revenue, i.e. 734 k€ to permanently finance. Between 2020 and 2023, WCR improved by 58 days of revenue, freeing up cash.

Operating WCR (2023) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

734 331 €

Customer credit (2023) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

131 j

Supplier credit (2023) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

441 j

Inventory turnover (2023) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

147 j

WCR in days of revenue (2023) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

300 j

WCR and payment terms evolution
ATLANCHIM PHARMA

Positioning of ATLANCHIM PHARMA in its sector

Comparison with sector Recherche-développement en autres sciences physiques et naturelles

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (26 transactions). This range of 239 898€ to 658 733€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2023
Indicative
239k€ 411k€ 658k€
411 261 € Range: 239 898€ - 658 733€
NAF 5 all-time
How is this estimate calculated?

This estimate is based on the analysis of 26 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Recherche-développement en autres sciences physiques et naturelles)

Compare ATLANCHIM PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Recherche-développement en autres sciences physiques et naturelles

Top companies in Recherche-développement en autres sciences physiques et naturelles

Largest companies by revenue in the sector Recherche-développement en autres sciences physiques et naturelles:

Top companies in Loire-Atlantique

Largest companies by revenue in the department Loire-Atlantique:

Voir le classement complet du département Loire-Atlantique

Frequently asked questions about ATLANCHIM PHARMA

What is the revenue of ATLANCHIM PHARMA ?

The revenue of ATLANCHIM PHARMA in 2023 is 881 k€.

Is ATLANCHIM PHARMA profitable?

ATLANCHIM PHARMA recorded a net loss in 2023.

Where is the headquarters of ATLANCHIM PHARMA ?

The headquarters of ATLANCHIM PHARMA is located in SAINT-HERBLAIN (44800), in the department Loire-Atlantique.

Where to find the tax return of ATLANCHIM PHARMA ?

The tax return of ATLANCHIM PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does ATLANCHIM PHARMA operate?

ATLANCHIM PHARMA operates in the sector Recherche-développement en autres sciences physiques et naturelles (NAF code 72.19Z). See the 'Sector positioning' section above to compare the company with its competitors.